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 ABSTRACT 
The design and synthesis of fullerene-steroid hybrids by using Prato’s protocol has afforded new 
fullerene derivatives endowed with epiandrosterone, an important naturally occurring steroid 
hormone.  Since the formation of the pyrrolidine ring resulting from the 1,3-dipolar cyloaddition 
reaction takes place with generation of a new stereogenic center on the C2 of the five member ring, 
the reaction proceeds with formation of a diastereomeric mixture [compounds 6 and 7 in 70:30 ratio, 
and 8 and 9 in 26:74 ratio (HPLC)] in which the formation of the major diasteroisomers 6 and 9 is 
consistent with an electrophilic attack of [60]fullerene by the Re face. The chiroptical properties of 
these conjugates reveal typical Cotton effects in CD spectra that have been used to assign the 
absolute configuration of the new  fulleropyrrolidines. The electrochemical study of the new 
compounds reveals the presence of four quasi-reversible reduction waves which are cathodically 
shifted in comparison with the parent C60.  
 
INTRODUCTION 
Although a large number of reactions with C60 have been reported so far,1 stereoselective additions 
have comparatively been less studied. The addition of azomethine ylides to C60 is one of the most 
powerful and versatile methods for derivatising fullerenes.2 In this regard, condensation of readily 
available starting materials such as α-amino acids and aldehydes gives rise to reactive 1,3-dipoles 
which efficiently add to C60 leading to functionalised fulleropyrrolidines.  
Recently, we have carried out a straightforward procedure catalyzed by silver or copper acetate to 
efficiently obtain pyrrolidino[60]fullerenes with stereochemical control by enantioselective 
cycloaddition of N-metalated azomethine ylides to the C60 molecule.3 This methodology was later 
extended to higher fullerenes, developing the first stereoselective  cycloaddition of N-metalated 
azomethine ylides to C70, thus achieving a selective control (site-, regio-, diastereo-, enantiocontrol) 
in the functionalization of higher fullerenes.4 Furthermore, the stereoselective synthesis of 1,3-
dipolar cycloadditions has also been extended to endohedral fullerenes, namely to a 
La@C72(C6H3Cl2) derivative.5 More recently, we have reported the stereodivergent syntheses of 
cis/trans pyrrolidino[3,4:1,2]fullerenes and endo/exo pyrrolidines with high enantioselectivity 
levels.6 
The formation of fulleropyrrolidines by 1,3-dipolar cycloaddition leads to planar intermediate 
ylides. Therefore an additional chiral centre on the α-amino acid or in the moiety containing the 
aldehyde group is thus required in order to achieve stereoselection. Thus, Prato et al. had previously 
applied this reaction to the preparation of chiral fulleroprolines, the absolute configurations of which 
were determined on the basis of experimental and calculated circular dichroism (CD) spectra.7 The 
diastereoselective synthesis of fulleropyrrolidines endowed with enantiomerically pure 
functionalized cyclobutanes has also been previously reported.8 
Recently, the synthesis of diastereoisomerically pure fulleropyrrolidines as chiral platforms for 
the design of optically active liquid crystals,9 and the diasteroselective preparation of fulleroprolines 
by lithium salt-assisted cycloaddition of azomethine ylides have been reported.10 
On the other hand, it is well-known that the principal obstacle for the potential use of C60 in bio-
medical applications is its complete lack of solubility in water and quite low solubility in almost all 
organic solvents.11 The covalent linkage of [60]fullerene with suitably funtionalized molecules is an 
efficient option to generate functional entities in which each part modulates the properties of the 
final compound and to achieve solubility. Thus, [60]fullerene has been covalently connected to 
aminoacids and peptides,12 oligonucleoides,13 steroids,14 and imidazonium salts,15 among others. 
In a previous work, we reported the design of new hybrids fullerene-steroid derivatives by using 
the Bingel–Hirsch protocol. Interestingly, treatment of [60]fullerene with malonates bearing 
cholesterol, β-sitosterol, and ergosterol moieties afforded hybrids exhibiting solubility in a variety of 
organic solvents.16 
Continuing our research in the synthesis of a new hybrid functionalized chimeras steroids-
fullerenes, in this paper we chose an important steroid for use as steroid platform: the 
epiandrosterone. This is a steroid hormone with weak androgenic activity and is the natural 
metabolite of dehydroepiandrosterone via the 5-alpha reductase enzyme, and has been shown to 
naturally occur in most mammals including pigs.17 Recent studies have found that epiandrosterone 
inhibits the pentose phosphate pathway (PPP) and dilates isolated blood vessels pre-contracted by 
partial depolarization. These results suggest that it may act as an antagonist of L-type Ca2+ channel 
with properties similar to those of 1,4-dihydropyridine (DHP) Ca2+ channel blockers.18 Also, this 
steroid can be used as synthetic intermediate for obtaining a wide range of compounds with 
biological activity, such as aminosteroids which find application as anti-arhythmic, hypotensive, 
anti-inflammatory, and fungicidal activity.19 Another example is the development of steroid-hetero 
systems (pyridines, thiophene, thiazole and pyrazole) which have potential anti-epileptic, 
antiprotozoal, antitumor and hypoglycemic bactericidal activities.20 
Remarkably, there are very few examples of steroid-fullerene hybrids reported so far. One of the 
first reports being the synthesis of fullerene bisadducts endowed with a steroid molecule.21. Other 
hybrids have also been prepared by Diels-Alder reaction from an steroidal diene and C60,22 and by 
1,3-dipolar cycloaddition in order to obtain fulleropyrrolidine derivatives.23-26 The aim of these 
investigations are directed to the search for functional hybrid molecules in which the characteristics 
of fullerenes may be changed, improved their solubility and biocompatibility, thus enabling further 
biological investigations.  
Taking into account the interest on the synthesis of steroids derivatives of fullerenes, here we 
report on the design of a diasteroselective synthesis of a new type of molecular chimeras through 
1,3-dipolar cycloaddition between azomethine ylides (generated in situ) and C60, by treatment of the 
corresponding formyl-substituted steroid with sarcosine and [60]fullerene by Prato’s protocol. The 
aim is the preparation of new fullerene–steroids hybrids with biological activity which is the 
ongoing theme of research in our group. 
 
 
RESULTS AND DISCUSSION  
Nowadays, there is an increasing interest in the combination of two privileged entities on the same 
scaffold. This procedure leads to hybrid molecules or conjugates with the goal of creating a chemical 
entity whose properties are more effective than its individual components. Ongoing interest in 
soluble fullerenes, as well as the difficulty of working with this molecular carbon allotrope, in this 
work we combine [60]fullerene with biologically active steroids. 
The fullerene steroids conjugates (6-9) were prepared by Prato reaction by treatment of 
[60]fullerene with the formyl-containing steroids. Therefore, the first step requires the preparation of 
the formyl derivatives 4 and 5 (See Scheme 1). 
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Scheme 1. Synthesis of  steroids-[60]fullerenes 6-9. (i) acetone, Jones´reagent, rt; (ii) acetic anhydride, 
pyridine, rt); (iii) POCl3, DMF, reflux; (iv) C60, N-methylglycine, toluene,  reflux. 
 
The convenient transformation of the hydroxyl group on C3 of the epiandrosterone (1) by 
oxidation gave the 5β-androstan-3,17-dione (2) and by acetylation gave the 3α-acetoxy-5β-
androstan-17-one (3) both with similar yields to those previously reported.27,28 The Vilsmeier–Haack 
reaction of 2 and 3 with phosphorus oxychloride and dimethylformamide in refluxing 
dichlorometane, gave the corresponding 3-chloro-2-formyl-17-oxo-5β-androstan-2-ene (4) and 3-α-
acetoxy-17-chloro-16-formyl-5β-androstan-16-ene (5), respectively. The reactions were monitored 
by TLC and the final compounds were obtained as white solids in good and moderate yields (78% 
and 50%, respectively) after basic hydrolysis with aqueous sodium acetate and purification by flash 
chromatography with a cyclohexane-ethyl acetate (4:1) mixture as the eluent. The new compounds 
were fully characterized by analytical and spectroscopic techniques (see Experimental Section). 
The 1H-NMR spectra of compounds 4 and 5 show the signals corresponding to the proton of the 
formyl group at ∼ 10 ppm. The principal differences in the spectrum of 4 in comparison with the 
unmodified steroid 2 resides in the disappearance of the signals corresponding to the methylene 
protons in C2 of the A ring, and the protons on C1 appear as two doublets at 1.75 ppm and 2.56 ppm 
(J = 17 Hz), which are deshielded in comparison with the same protons in compound 2. The rest of 
the signals are quite similar in position and multiplicity. 13C-NMR spectrum of 4 shows the carbon 
of the CHO group at 191.35 ppm and the two new Csp2 on ring A at 133.00 (C2) and 149.57 (C3) 
ppm.  
NMR spectra of compound 5 show the transformation that has occurred in ring D. Signals 
corresponding to the protons attached to C16 in the 1H-NMR spectrum and the signal of the C=O 
group on C17 in the 13C-NMR spectrum disappear and, in the 13C-NMR spectrum, two new signals 
assignable to C16 and C17 joined by a double bond at 136.42 ppm and 162.60 ppm respectively, and 
at 188.15 ppm the signal corresponding to the CHO group are observed.  
The chemical structures of the new compounds were ascertained by MS. Under ESI conditions, 
compounds 4 and 5 show sodium adducts peaks at m/z = 357.2 [M + Na]+, and 401.2 [M + Na]+, 
respectively.  
The synthesis of N-methyl-2-substituted pyrrolidino[ 3,4:1,2][60]fullerenes  was carried out by 
1,3-dipolar cycloaddition of the in situ generated azomethine ylides to C60 by following Prato’s 
procedure. Thus, a mixture of the corresponding chloroformyl steroid 4 or 5, C60, and sarcosine (N-
methylglycine) was refluxed in toluene under argon atmosphere for 6 h (see Scheme 1). The color of 
the solution changed from purple to brown.  
The HPLC chromatogram of the reaction mixture (toluene/acetonitrile 9:1; 1 mLmin–1) for 
enantiopure 4, shows peaks at 8.71 and 9.33 min. As the the cyclization to afford the pyrrolidine ring 
takes place with generation of a new stereogenic center on the C2 of the five member ring, and the 
configuration of the steroid is fixed, the reaction give rise to a diasteromeric mixture of compounds 6 
and 7 in 70:30 ratio (HPLC).  
Under the same reaction conditions, 5 afforded to the mixture of the diasteromers 8 and 9 with 
retention time under the same HPLC conditions, of 5.29 and 7.03 min in 26:74 ratio (HPLC). In each 
of these chromatograms an additional peak, assigned to the C60 starting material, appears at 9.84 
min, together with other minor peaks attributed to the formation of bis-cycloadducts. 
The mixture of diasteromers was easily separated by purification by flash chromatography, initially 
with carbon disulfide to elute unreacted C60, followed by dichlorometane or toluene, compounds 6, 
7, 8, and 9 were obtained in 42%, 31%, 28%, and 47 % yields, respectively, as stable brown solids. 
The moderate stereoselectivity, that affords to the diasteroisomer 6 and 9 as main products, is 
consistent with an electrophilic attack of [60]fullerene onto the Re face of the 1,3 dipole. This is 
probably due to a more stable planar arrangement of the π coniugated system, dipole and steroid 
double bond, in a W shape with respect to the S conformation. In this W conformation, the presence 
of steroid group hampers the addition from the Si face and favors the approximation from the Re 
face giving rise the corresponding two diastereoisomers in a 6:4 ratio.  
 
Figure 1. Plausible attack of C60 onto the Re less hindered face of the azomethine-steroid ylide. 
 
1H NMR spectroscopy revealed the presence of C60–steroid hybrids. Besides the disappearance of 
the formyl proton (signal at δ  ∼ 10 ppm) in the fulleropyrrolidines 6, 7, 8, and 9, new signals 
corresponding to the protons of the pyrrolidine ring appeare at δ 4.16 and 4.90 (6), δ 4.18 and 4.94 
(7), δ 4.65 and 4.90 (8), and δ 4.08 and 4.18 (9) as doublets (J ∼ 9 Hz; geminal hydrogens). The 
proton attached to C2 of the pyrrolidine ring is observed at δ 5.30 for 6 and 7 and ∼ 5.05 ppm for 8 
and 9. The N-methyl protons appear at 2.75 (6), 2.84 (7), 2.83 (8) and 2.80 (9) ppm. The rest of the 
signals are in agreement with the data reported for steroids 4 and 5, (see Experimental Section). 
On the other hand, the number of signals observed in the 13C NMR spectra reveal the lack of 
symmetry in these compounds. The 13C NMR spectra of 6, 7, 8, and 9 show the presence of the 
signals of the 6,6-ring junction of the C60 framework at ∼ 69 ppm and ∼75 ppm. For compounds 6 
and 7, the signals of the carbons of the fulleropyrrolidine ring appear at ∼79 ppm (C2) and ∼70 ppm  
(C5), while these signals for compounds 8 and 9 appear at ∼76 and  ∼69 ppm respectively. The 
positions of the remaining steroid carbon atoms are relatively insensitive to the presence of the C60 
cage, and there are no significant variations in the chemical shifts. 
MS allowed the proposed structures to be verified. The ESI spectrum for compound 6 shows a 
peak at m/z = 1082.22424 which corresponds to [M+ H]+. The isolation and subsequent 
fragmentation of this ion under CDI conditions reveals that the retro-Prato reaction cannot take place 
due to the protonation of the nitrogen atom of the pyrrolidine ring, similarly to other results recently 
reported by us.29 However, in the negative mode of detection the corresponding deprotonated 
molecule [M-H]-, m/z = 1081.18888 undergoes two different fragmentations. The first one 
corresponds to a loss of a hydrochloride molecule forming a fragment at m/z 1045.21318. The 
second fragmentation takes place via a retrocycloaddition process to form a parent fullerene ion at 
m/z 719.98761.  
In the ESI positive mode of ionization, compound 7 shows a peak at 1082.22414 corresponding to 
[M + H]+. The retrocycloaddition reaction is not observed due to the protonation of the pyrrolidine 
nitrogen atom.  
The MALDI-TOF and ESI mass spectra for compounds 8 and 9 show peaks at m/z = 1126.245 
and 1126.25072, respectively, corresponding to the [M + H]+. The MS2 spectrum reveals a total 
inhibition of the retrocycloaddition reaction.29 
We investigated also the possible existence, for each diasteroisomer, of atropoisomers as result of a 
restricted rotation around the pyrrolidine-steroid bond. To this aim, we performed computational 
studies and variable-temperature NMR experiment with the compounds XXX. The 1H NMR spectra 
recorded in CD2Cl2  over a range of temperatures (from -60 ºC to 70 °C) showed only slight changes 
in the shift of some signals and no dynamic process could be appreciated. Even at –60 °C, the 
dynamic exchange between the two potential atropoisomers is enough fast on the NMR timescale 
and the resulting spectrum is therefore the average of both rotamers. 
We have calculated by means of accurate quantum-chemical (Density Functional Theory) methods 
the (fully relaxed and with a tight grid) torsion energy profiles resulting from single bond rotation 
around the pyrrolidine–steroid bond, which clearly allows distinguish the existence of a pair of 
minimum, A and B, at approximately 42 and 190 degrees (see Figure 2). Note that intramolecular 
(non-covalent) dispersion interactions(Ref1,Ref2), which are expected to highly influence the mutual 
orientation between the fullerene and steroid moieties, are explicitly considered into these 
calculations, and that the cost-effective SVP basis set was considered here although the conclusions 
are not expected to vary upon further basis set extensions. 
However, the energy separation between these two rotamers is close to converge to a value of 
around 7 kcal/mol, independently of the method chosen, which also include now highly 
sophisticated DFT-based extensions believed to be of sufficiently large accuracy(Ref3,Ref4). This is 
well below of the value reported for related fullerene derivatives which displayed the presence of 
atropoisomers. Indeed, Nierengarten et al. reported a slow dynamic exchange, observable with NMR 
experiment, between two atropisomers only at -40 ºC for an energy barrier of 15 Kcal/mol.30 
 Figure 2. Torsion energy profiles of compound 6, calculated with various DFT methods. 
 
The solution electrochemistry of the fullerene-steroids hybrids 6-9 was investigated by cyclic 
voltammetry (CV) and Osteryoung Square Wave Voltammetry (OSWV). The redox potentials are 
summarized in Table 1. 
         
 
 
 
 
 Table 1. Redox Potentials of fullerene derivatives 6-9 vs Ferrocene in THF (V).a 
Compound E11/2, red E21/2, red E31/2, red E41/2, red 
 6 -1.02 -1.60 -2.25 -2.78b 
 7 -0.98 -1.55 -2.16 -2.65b 
 8 -0.98 -1.54 -2.17 -2.64b 
 9 -0.94 -1.51 -2.16b -2.67b 
C60 -0.90c 1.49c -2.06c -2.56c 
   ªWorking electrode: glassy carbon electrode; counter electrode: Pt; reference electrode: Ag/AgNO3. 
Supporting electrolyte: TBAPF6. Scan rate: 0.1 Vs−1. E1/2=(Epa+Epc)/2, where Epc and Epa = cathodic and 
anodic peak potentials, respectively. b From OSWV. c From reference 33, using TBAClO4 as supporting 
electrolyte. 
 
All fulleropyrrolidine derivatives exhibit four quasi-reversible reduction waves in the investigated 
solvent window (Figure 1). As expected, these reduction values are cathodically shifted (∆E = 0.12-
0.04 V) in comparison with the parent C60,31 a consequence that stems from saturating a double bond 
of the C60 core, which raises the LUMO energy. In this sense, and in addition to the thoroughtful 
spectroscopic characterization carried out on these compounds and discussed above, the 
electrochemical studies further demonstrated the formation of fulleropyrrolidine monoadducts. 
 
Figure 3. Cyclic voltammograms of 6 in THF, 0.1 M TBAPF6, with a scan rate of 0.1 V/s. 
 
Furthermore, the absence of significant potential shifts with respect to other fulleropyrrolidine 
monoadducts indicate that there is essentially no effect of the steroidic unit on the electronic 
properties of the C60 core.32 
Inspection of the CD spectra shows that diastereoisomeric pairs 6, 7 and 8, 9 give nicely opposite 
signed curves in the 430 nm region of the electronic spectra, thus confirming opposite configurations 
in the new stereogenic center (see Figure 4). This relevant UV–visible band is considered the 
fingerprint for all fullerene monoadducts at 6,6 junctions (between two fused hexagons) regardless 
of the nature of the organic addend saturating the double bond.  In order to assigned the absolute 
configuration of the new stereogenic carbon formed on C2 of the pyrrolidine ring, we take into 
account the sector rule,33-35 which links Cotton effect (CE) associated with this diagnostic UV–vis 
band and the stereochemical environment around the 6,6 junction. Using this rule we have 
determined the absolute configuration of C2 for compounds 6 (2R), 7 (2S), 8 (2S), 9 (2R) (See 
Scheme 1 and Supporting information).  
 
 
Figure 4. CD spectra of fulleroyrrolidines (6-9)  in CH2Cl2 (conc, 4 x 10-4 M).  
 
CONCLUSIONS 
We have carried out the synthesis of new [60]fullerene–steroid hybrids as functional chimeras (6, 7, 
8, and 9) by using Prato´s reaction of the corresponding steroid-containing formyl group  (4 and 5) 
with C60. The reactions are sensitive to steric factors and C60 reacts with good diastereoselectivity 
with bulky chiral reagents. A thorough spectroscopic, computational and analytical study has 
allowed the chemical structures of the new fulleropyrrolidines to be unambiguously determined. The 
resulting chiral adducts exhibit chiroptical properties, with typical Cotton effects in CD spectra that 
can be used to assign the absolute configuration to fulleropyrrolidines. The new hybrid compounds 
(6, 7, 8, and 9), bearing fullerene and steroid units in the same molecule, can be considered 
promising functional chimeras, with potential biomedical applications  
 EXPERIMENTAL SECTION  
General: All reactions were performed using an atmosphere of argon and oven-dried glassware. 
Solvents were dried by standard procedures. All reagents were of commercial quality and were used 
as supplied unless otherwise specified. Reactions were monitored by thin-layer chromatography 
carried out on 0.25 mm silica gel plates (230-400 mesh). Flash column chromatographies were 
performed using silica gel (60 Å, 32–63 µm). FTIR spectra were recorded with a Tensor 27 (ATR 
device) spectrometer in CHCl3. 1H NMR spectra were recorded at 700 MHz, and 13C NMR at 175 
MHz, with a Avance III instrument; the one-bond heteronuclear correlation (HMQC) and the long-
range 1H–13C correlation (HMBC) spectra were obtained by use of the inv4gs and the inv4gslplrnd 
programs. HRMS-ESI spectra were recorded with an FTMS APEX Q-IV instrument at 4.7 T, and 
HRMS-MALDI (dithranol as matrix) in an Applied Biosystem 4700 Reflector machine. UV/Vis 
spectra were recorded in CHCl3. Microanalysis was performed with 2400 CHN instrument. An 
Agilent 1100 high-performance liquid chromatography (HPLC) system was used to determine the 
purity  of the compounds synthesized. A BuckyPrep column (column dimensions, 4.6 x 250 mm; 
flow rate 1.0 mLmin–1, injection volume 15 µL, eluente mixture toluene:acetonitrile 9:1) was 
employed. The retention times (tRs) and the peak areas (PAs) reported were determined at a 
wavelength of 320 nm. Electrochemical measurements were performed with an Autolab PGStat 30 
instrument with a three-electrode configuration system. The measurements were carried out with 
THF solutions [0.1 M in tetrabutylammonium hexafluorophosphate (TBAPF6)]. A glassy carbon 
electrode (3 mm diameter) was used as the working electrode, and a platinum wire and an 
Ag/AgNO3 electrode were employed as the counter and the reference electrode, respectively. 
Ferrocene (Fc) was added as an internal reference, and all the potentials were determined relative to 
the Fc/Fc+ couple. Both the counter and the reference electrodes were directly immersed in the 
electrolyte solution. The surface of the working electrode was polished with commercial alumina 
prior to use. Solutions were stirred and deaerated by bubbling argon for a few minutes prior to each 
measurements. Unless otherwise specified, the scan rate was 100 mV/s.  
Theoretical results: All calculations shown here were performed with the ORCA 2.8.0 package(Ref5) 
and employ larger-than-default numerical thresholds. Furthermore, the RI- and COSX-based 
techniques were also used to alleviate the computational cost when needed. The BLYP, B3LYP, and 
B2-PLYP exchange-correlation functionals, which allows to explore the dependence of the results 
upon sophistication of the underlying expressions, were always used with the corresponding 
dispersion correction (-D) for weakly overlapping molecular fragments.  
Synthesis of compounds. 
5β-androstan-3,17-dione (2). This compound was prepared by following the method previously 
reported in the literature in 85 % yield, m.p. 130–132 ºC. (lit. 129-131 oC).26 
3α-acetoxy-5β-androstan-17-one (3). This compound was prepared by following the method 
previously reported in the literature in 80 % yield, m.p. 103 – 104 ºC (lit 106-108 oC)27  
3-Chloro-2-formyl-17-oxo-5β-androstan-2-ene (4). To a stirred cold (0–5 ºC) mixture of 
phosphorus oxychloride (1.6 ml) and dimethylformamide (1.3 ml), a solution of 5β-androstan-3,17-
dione (2) (1.25 g, 9 mmol) in dichloromethane (20 ml) was added dropwise. The reaction mixture 
was allowed to attain room temperature and then refluxed under argon for 18 hours. The mixture 
was added to a solution of sodium acetate (40 g in 100 ml of water) and stirred at room temperature 
for one hour. The mixture was extracted with dichlorometane and the organic phase was washed 
twice with water and subsequently dried with anhydrous sodium sulfate. The organic extracted was 
concentrated and the solid obtained was purified by column chromatography using a mobile phase, 
cyclohexane-ethyl acetate (4:1). The product was isolated as a white solid, yield 78 %, m.p. 140–142 
ºC. IR (CHCl3) υmax 2923, 1738, 1676, 1625, 1448, 1149 cm−1;   1H NMR (700 MHz), CDCl3) δ   
0.76 (s, 3H, CH3-C10), 0.83 (m, 1H, H9), 0.88 (s, 3H, CH3-C13), 1.27 (m, 1H, H12), 1.27 (m, 1H, 
H14), 1.27 (m, 1H, H6), 1.42 (m, 1H, H11), 1.51 (m, 1H, H15), 1.57 (m, 1H, H5), 1.58 (m, 1H, H6), 
1.62 (m, 1H, H8), 1.75 (d, J = 17.0 Hz,1H, H1), 1.75 (m, 1H, H11), 1.80 (m, 1H, H7), 1.84 (m, 1H, 
H12), 1.84 (m, 1H, H7), 1.90 (m, 1H, H15), 2.07 (m, 1H, H16), 2.35 (m, 1H, H4), 2.45 (m, 1H, H4), 
2.44 (m, 1H, H16), 2.56 (d, J = 17.0 Hz,1H, H1), 10.18 (s, 1H, CHO); 13C NMR (175 MHz, CDCl3) 
δ 11.66 (CH3-C10), 13.73 (CH3-C13), 20.43 (C11), 21.73 (C15), 27.35 (C6), 30.18 (C7), 31.37 
(C12), 34.88 (C8), 34.30 (C10), 35.76 (C16), 37.78 (C1), 40.24 (C4), 42.42 (C5), 46.63 (C13), 51.19 
(C14), 56.43 (C9), 133.00 (C2), 149.57 (C3), 191.35 (CHO), 220.89 (C17). MS (ESI): 357.2 [M + 
Na]+. Anal. Calcd. for: C, 71.73; H, 8.13. Found: C, 71.67; H, 8.20. 
3-α-acetoxy-17-chloro-16-formyl-5β-androstan-16-ene (5). To a stirred cold (0–5 ºC) mixture 
of phosphorus oxychloride (10 mL) and dimethylformamide (10 mL), a solution of 3β-acetoxy-5α-
androstan-17-one (2 g, 6 mmol) in chloroform (40 mL) was added dropwise. The reaction mixture 
was allowed to attain room temperature and then refluxed under argon for 5 hours. The mixture was 
added to a solution of sodium acetate (40g in 100 ml of water) and stirred at room temperature for 
one hour. The mixture was extracted with dichlorometane and the organic phase was washed twice 
with water and subsequently dried with anhydrous sodium sulfate. The organic extracted was 
concentrated and the solid obtained was purified by column chromatography using as mobile phase, 
cyclohexane- ethyl acetate (4:1). The product was isolated as a white solid, yield 50 %, m. p. 130–
132 ºC. IR ( CHCl3) υmax 2939, 1732, 1673, 1587, 1243, 1025 cm−1;  1H NMR (700 MHz), CDCl3) δ   
0.78 (m, 1H, H9), 0.87 (s, 3H, CH3-C10), 0.97 (s, 3H, CH3-C13), 0.98 (m, 1H, H7), 1.05 (m, 1H, 
H1), 1.20 (m, 1H, H5), 1.30 (m, 1H, H6), 1.33 (m, 1H, H6), 1.37 (m, 1H, H4), 1.41 (m, 2H, H11, 
H12), 1.50 (m, 1H, H14), 1.51 (m, 1H, H2), 1.60 (m, 1H, H8),1.61 (m, 1H, H4), 1.72 (m, 1H, H1), 
1.73 (m, 1H, H7), 1.83 (m, 1H, H2), 2.03 (s, 3H, CH3-CO), 1.84 (m, 1H, H12), 2.04 (m, 1H, H15), 
2.53 (m, 1H, H15), 4.70 (m, 1H, H3), 10.02 (s, 1H, CHO); 13C NMR (175 MHz, CDCl3) δ 12.30 
(CH3-C10), 15.20 (CH3-C13), 20.60 (C11), 21.46 (CH3-CO), 27.37 (C4), 27.37 (C2), 28.20 (C6), 
28.30 (C15), 31.00 (C7), 32.90 (C12), 33.38 (C8), 35.80 (C10), 36.46 (C1), 44.76 (C5), 50.90 (C13), 
53.61 (C14), 54.42 (C9), 73.43 (C3), 136.42 (C16), 162.60 (C17), 170.68 (COO), 188.15 (CHO). 
MS (ESI): 401.2 [M + Na]+. Anal. Calcd for C22H31ClO3: C, 69.73; H, 8.25. Found: C, 69.66; H, 
8.18. 
Synthesis of N-methyl-2-substitutedpyrrolidino[ 3,4:1,2][60]fullerenes (6, 7, 8, 9). A mixture 
of C60 (0.15 mmol), N-methylglycine (0.76 mmol), and the corresponding chloroformyl steroid (4 or 
5) in toluene (250 mL) under argon atmosphere was refluxed for 6 h.  The color of the solution 
changed from purple to brown. The solvent was removed under reduced pressure and the solid 
residue thus obtained was purified by column chromatography on silica gel, using CS2 to elute 
unreacted C60 and dichloromethane to elute the corresponding pyrrolidino[3,4:1,2][60]fullerene. 
Additional purification of these compounds was carried out by repetitive precipitation and 
centrifugation using hexane, methanol and diethyl ether as solvents. 
N-Methyl-2(R)-(3´-chloro-17´-oxo-(5β–antrostan-2´-en-2-yl)pyrrolidino[3,4:1,2][60] 
fullerene (6). HPLC: BuckyPrep, toluene/acetonitrile (9:1), flow rate 1 mL/min, tR = 8.71 min. The 
purification of 6 was performed by column chromatography on silica gel with CS2 and 
dichlorometane as the eluents. This compound was obtained in 42 % yield (57% based on recovered 
C60). [α]D20 = +185 (c 2 x 10-4 CH2Cl2). Brown solid. UV/Vis: λmax (log ε) = 425 (3.70), 325 
(4.31), 258 (4.52) nm. IR ( CHCl3) υmax 2961, 2919, 2850, 1737, 1447, 1261, 1098,  802, 753, 665 
cm−1. 1H NMR (700 MHz, CDCl3) δ  0.74 (m, 1H, H9´), 0.93 (s, 3H, CH3-C13´), 0.96 (m, 1H, H7´), 
1.06 (s, 3H, CH3-C10´), 1.29 (m, 1H, H6´), 1.30 (m, 1H, H14´), 1.32 (m, 1H, H12´), 1.44 (m, 1H, 
H5´), 1.53 (m, 1H, H15´), 1.54 (m, 1H, H6´), 1.55 (m, 1H, H11´), 1.58 (m, 1H, H8´), 1.82 (m, 1H, 
H7´), 1.90 (m, 1H, H12´), 1.91 (m, 1H, H11´), 1.96 (m, 1H, H15´), 2.03 (d, J = 17.7 Hz,1H, H1´), 
2.08 (m, 1H, H16´), 2.30 (m, 1H, H4´), 2.39 (m, 1H, H4´), 2.46 (m, 1H, H16´), 2.75 (s, 3H, CH3-N), 
2.95 (d, J = 17.7 Hz,1H, H1´), 4.18 (d, J = 9.4 Hz, H5 pyrrolidine ring), 4.90 (d, J = 9.4 Hz, H5 
pyrrolidine ring), 5.30 (s, 1H, H2-pyrrolidine ring). 13C NMR (175 MHz, CDCl3) δ 11.98 (CH3-
C10´), 13.78 (CH3-C13´), 20.74 (C11´), 21.80 (C15´), 27.54 (C6´), 30.12 (C7´), 31.44 (C12´), 35.36 
(C10´), 35.80 (C8´), 35.85 (C16´), 39.33 (C4´), 40.39 (CH3-N), 41.11 (C1´), 43.08 (C5´), 47.67 
(C13´), 51.16 (C14´), 53.75 (C9´), 69.74 (Csp3 C60), 69.68 (C5 pyrrolidine ring), 75.45 (Csp3 C60), 
79.67 (C2 pyrrolidine ring), 128.32 (C2´), 133.43 (C3´), 135.65, 134.92, 136.77, 139.72, 139.98, 
140.05, 140.27, 141.74, 141.83, 141.93, 142.08, 142.15, 142.17, 142.19, 142.23, 142.25, 142.60, 
142.65, 144.37, 142.69, 143.17, 143.06, 144.43, 144.53, 144.68, 145.16, 145.26, 145.31, 145.39, 
145.48, 145.52, 145.65, 145.80, 146.01, 146.03,, 146.06, 146.08, 146.19, 146.22146.39, 146.35, 
146.64, 147.30, 153.75, 154.51, 154.54, 156.15, 221.14 (C17´). HRMS (ESI): [M+ H]+ = 
1082.22424. Calculated for C82H33ClNO, 1082.22451 
N-Methyl-2(S)-(3´-chloro-17´-oxo-(5β–antrostan-2´-en-2-yl)pyrrolidino[3,4:1,2] 
[60]fullerene (7). HPLC: BuckyPrep, toluene/acetonitrile (9:1), flow rate 1 mL/min, tR = 9.33 min. 
The purification of 7 was performed by column chromatography on silica gel with CS2 and 
dichlorometane as the eluents. This compound was obtained in 31 % yield (43% based on recovered 
C60). [α]D20 = +75 (c 2 x 10-4 CH2Cl2). Brown solid. UV/Vis: λmax (log ε) = 425 (3.70), 325 (4.31), 
258 (4.52) nm. IR (CHCl3) υmax 2925, 2850, 1734, 1544, 1460, 1373, 1081, 1022, 868, 801, 667 
cm−1.  1H NMR (700 MHz, CDCl3) δ 0.56 (s, 3H, CH3-C10´), 0.87 (s, 3H, CH3-C13´), 0.90 (m, 1H, 
H9´), 1.04 (m, 1H, H7´), 1.25 (m, 1H, H6´), 1.31 (m, 1H, H12´), 1.32 (m, 1H, H11´), 1.32 (m, 1H, 
H14´), 1.51 (m, 1H, H8´), 1.52 (m, 1H, H15´), 1.57 (m, 1H, H6´), 1.72 (m, 1H, H5´), 1.84 (m, 1H, 
H7´), 1.85 (m, 1H, H11´), 1.87 (m, 1H, H12´), 1.97 (m, 1H, H15´), 2.10 (m, 1H, H16´), 2.23 (m, 1H, 
H1´), 2.29 (m, 1H, H4´), 2.41 (m, 1H, H4´), 2.48 (m, 1H, H16´), 2.84 (s, 3H, CH3-N), 3.12 (d, J = 
16.5 Hz,1H, H1´), 4.18 (d, J = 9.3 Hz, H5 pyrrolidine ring), 4.94 (d, J = 9.3 Hz, H5 pyrrolidine 
ring), 5.30 (s, 1H, H2 pyrrolidine ring). 13C NMR (175 MHz, CDCl3) δ 11.68 (CH3-C10´), 13.86 
(CH3-C13´), 20.46 (C11´), 21.73 (C15´), 27.26 (C6´), 30.29 (C7´), 31.49 (C12´), 34.94 (C10´), 
35.10 (C8´), 35.80 (C16´), 39.33 (C4´), 41.37 (CH3-N), 41.41 (C1´), 43.10 (C5´), 47.70 (C13´), 
51.70 (C14´), 54.30 (C9´), 69.89 (Csp3 C60), 70.02 (C5 pyrrolidine ring), 75.59 (Csp3 C60), 79.26 
(C2 pyrrolidine ring), 128.50 (C2´), 133.40 (C3´), 135.41, 134.93, 136.34, 137.01, 139.87, 139.35, 
140.11, 140.33, 141.52, 141.81, 141.88, 141.90, 142.06, 142.10, 142.13, 142.17, 142.19, 142.22, 
142.26, 142.28, 142.61, 142.66, 142.70, 143.06, 143.11, 144.37, 144.44, 144.59, 145.17, 145.23, 
145.32, 145.38, 145.42, 145.44, 145.65, 145.67, 145.88, 146.03, 146.06, 146.12,146.19, 146.23, 
146.29, 146.39, 146.48, 146.95, 147.28, 147.33, 152.92, 154.69, 154.80, 156.02, 221.17 (C17´). 
HRMS (ESI): [M+ H]+ = 1082.22414. Calculated for C82H33ClNO, 1082.22451 
N-Methyl-2(R)-(3´-α-acetoxy-17´-chloro-5β-androstan-16-en-2-yl)pyrrolidino[3,4:1,2] 
[60]fullerene (8). HPLC: BuckyPrep, toluene/acetonitrile (9:1), flow rate 1 mL/min–1, tR = 5.29 
min. The purification of 8 was performed by column chromatography on silica gel with CS2 and 
toluene as the eluents. This compound was obtained in 28 % yield (36% based on recovered C60). 
[α]D
20 = +90 (c 2 x 10-4 CH2Cl2). Brown solid. UV/Vis: λmax (log ε) = 425 (3.70), 325 (4.31), 258 
(4.52) nm. IR ( CHCl3) υmax 2923, 2852, 2786, 1730, 1628, 1245, 1028, 1245, 1026, 757, 660 cm−1. 
1H NMR (700 MHz, CDCl3) δ 0.67 (m, 1H, H9´), 0.76 (m, 1H, H7´), 0.87 (s, 3H, CH3-C10´), 1.01 
(td, J = 14.3 Hz, J =3.7 Hz, 1H, H1´), 1.08 (s, 3H, CH3-C13´), 1.16 (m, 1H, H5´), 1.20 (m, 1H, 
H12´), 1.30 (m, 2H, H6´), 1.30 (m, 1H, H14´), 1.35 (m, 1H, H4´), 1.37 (m, 1H, H11´), 1.48 (m, 1H, 
H2´), 1.59 (m, 1H, H4´), 1.60 (m, 1H, H8´), 1.61 (m, 1H, H11´), 1.68 (dt, J = 13.3 Hz, J = 3.3 Hz, 
1H, H1´), 1.73 (m, 1H, H7´), 1.77 (m, 1H, H12´), 1.80 (m, 1H, H2´), 2.02 (s, 3H, CH3-CO), 2.42 (m, 
1H, H15´), 2.80 (m, 1H, H15´), 2.83 (s, 3H, CH3-N), 4.18 (d, J= 9.7Hz, 1H, H5 pyrrolidine ring), 
4.65 (m, 1H, H3), 4.90 (d, J= 9.7 Hz, 1H, H5 pyrrolidine ring), 5.05 (s, 1H, H2 pyrrolidine ring). 13C 
NMR (175 MHz, CDCl3) δ 12.17 (CH3-C10´), 15.54 (CH3-C13´), 20.69 (C11´), 21.46 (CH3-CO), 
27.38 (C2´), 28.30 (C6´), 31.16 (C7´), 32.07 (C15´), 33.90 (C4´), 33.80 (C8´), 34.23 (C12´), 35.70 
(C10´), 36.30 (C1´), 44.62 (C5´), 48.60 (CH3-N), 48.90 (C13´), 54.45 (C9´), 54.96 (C14´), 69.76 
(Csp3 C60), 69.99 (C5, pyrrolidine ring), 73.42 (C3), 75.95 (Csp3 C60), 76.16 (C2 pyrrolidine ring), 
133.60 (C16´), 135.31, 135.75, 136.37, 136.70, 139.42, 140.07, 140.23, 141.59, 141.79, 141.86, 
141.99, 142.05, 142.08, 142.14, 142.15, 142.19, 142.21, 142.24, 142.60, 142.66, 142.71, 143.05, 
143.19, 144.39, 144.45, 144.65, 144.71, 145.19, 145.28, 145.35, 145.38, 145.39, 145.42, 145.45, 
145.46, 145.51, 145.61, 145.80, 146.00 (C17´), 146.05, 146.08, 146.13, 146.21, 146.22, 146.26, 
146.34, 146.38, 146.45, 146.60, 146.67, 147.31, 147.36, 152.89, 153.96, 154.14, 155.96, 170.64 
(COO). MALDI-TOF: [M + H]+ = 1126.245. Calculated for C84H37ClNO2, 1126.250. ESI [M + H]+ 
= 1126.25446. Calculated for C84H37ClNO2, 1126.25128. 
N-Methyl-2(S)-(3´-α-acetoxy-17´-chloro-5β-androstan-16-en-2-yl) 
pyrrolidino[3,4:1,2][60]fullerene (9). HPLC: BuckyPrep, toluene/acetonitrile (9:1), flow rate 1 
mL/min, tR = 7.03 min. The purification of 7 was performed by column chromatography on silica 
gel with CS2 and toluene as the eluents. This compound was obtained in 47 % yield (66 % based on 
recovered C60). [α]D20 = +65 (c 2 x 10-4 CH2Cl2). Brown solid. UV/Vis: λmax (log ε) = 425 (3.70), 
325 (4.31), 258 (4.52) nm. IR ( CHCl3) υmax 2923, 2853, 2789, 1734, 1628, 1258, 1092, 1024, 801, 
706 cm−1. 1H NMR (700 MHz, CDCl3) δ 0.78 (s, 3H, CH3-C13´), 0.86 (s, 3H, CH3-C10´), 0.88 (m, 
1H, H9´), 1.10 (m, 1H, H1´), 1.26 (m, 1H, H5´), 1.29 (m, 2H, H6´), 1.32 (m, 1H, H7´), 1.38 (m, 1H, 
H11´), 1.39 (m, 1H, H4´), 1.45 (m, 1H, H12´), 1.53 (m, 1H, H2´), 1.58 (m, 1H, H8´), 1.64 (m, 1H, 
H4´), 1.67 (m, 1H, H12´), 1.68 (m, 1H, H14´), 1.71 (m, 1H, H11´), 1.77 (m, 1H, H1´), 1.84 (m, 1H, 
H7´), 1.85 (m, 1H, H2´), 2.05 (s, 3H, CH3-CO), 2.15 (m, 1H, H15´), 2.80 (m, 1H, H15´), 2.80 (s, 
3H, CH3-N), 4.72 (m, 1H, H3´), 4.08 (d, J= 9.0 Hz, 1H, H5-pyrrolidine ring), 4.18 (d, J= 9.0 Hz, 
1H, H5-pyrrolidine ring), 5.02 (s, 1H, H2 pyrrolidine ring). 13C NMR (175 MHz, CDCl3) δ 12.29 
(CH3-C10´), 16.18 (CH3-C13´), 20.94 (C11´), 21.43 (CH3-CO), 27.54 (C2´), 29.94 (C6´), 32.17 
(C15´), 31.54 (C7´), 33.77 (C12´), 34.07 (C4´), 34.16 (C8´), 35.85 (C10´), 36.70 (C1´), 40.38 (CH3-
N), 45.06 (C5´), 49.19 (C13´), 55.68 (C14´), 54.80 (C9´), 69.84 (Csp3 C60), 69.67 (C5 pyrrolidine 
ring), 71.51 (C3´), 75.54 (Csp3 C60), 76.49 (C2 pyrrolidine ring), 133.36 (C16´), 135.47, 135.80, 
136.38, 136.88, 139.50, 140.11, 140.14, 140.32, 141.85, 141.90, 141,95, 142.05, 142.14, 142.20, 
142.23, 142.30, 142.64, 142.68, 142.71, 142.73, 143.08, 144.39, 144.47, 144.61, 144.72, 145.19, 
145.25, 145.35,  145.41, 145.48, 145.53, 145.64, 145.78, 146.04, 146.06, 146.09, 146.12, 146.23, 
146.31, 146.35, 146.37, 146.54, 147.31 (C17´), 147.49, 153.36, 154.07, 154.31, 155.09, 170.45 
(COO). ESI: [M +`H]+ = 1126.25072. Calculated for C84H37ClNO2, 1126.25128 
 
Supporting Information  
Spectral data for all compounds, HPLC chromatograms of the reactions mixture and pure products, 
absolute configuration assignement, and xyz coordinates (B3LYP-D3/SVP) of the atropoisomers 
found (6). This material is available free of charge via the Internet at http://pubs.acs.org. 
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